相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Many roads lead to Rome: The FGF4-AMP-activated protein kinase-Caspase 6 signal axis in NAFLD and NASH
Alena Laschtowitz et al.
HEPATOLOGY (2022)
Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Tobias Puengel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon et al.
GUT (2021)
Immunological mechanisms and therapeutic targets of fatty liver diseases
Hua Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
Manal F. Abdelmalek et al.
CONTEMPORARY CLINICAL TRIALS (2021)
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Rohit Loomba et al.
CELL (2021)
Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis
Oliver Krenkel et al.
GUT (2020)
Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design
Quentin M. Anstee et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
Michael Ritchie et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: opportunities and challenges
Sander Lefere et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
Vlad Ratziu et al.
HEPATOLOGY (2020)
New drugs for NAFLD: lessons from basic models to the clinic
Katharina C. Reimer et al.
HEPATOLOGY INTERNATIONAL (2020)
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Zobair Younossi et al.
HEPATOLOGY (2019)
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Amedeo Lonardo et al.
HEPATOLOGY (2019)
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD
Mary E. Rinella et al.
JOURNAL OF HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Fibroblast growth factor 21 in non-alcoholic fatty liver disease
Bradley Tucker et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
Sander Lefere et al.
JHEP REPORTS (2019)
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
Oliver Krenkel et al.
HEPATOLOGY (2018)
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman et al.
HEPATOLOGY (2018)
Effects of a PEGylated fibroblast growth factor 21 variant on steatosis, inflammation, and fibrosis in a mouse model of non-alcoholic steatohepatitis
B. Zinker et al.
JOURNAL OF HEPATOLOGY (2018)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes et al.
JOURNAL OF HEPATOLOGY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
An update on the recent advances in antifibrotic therapy
Frank Tacke et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
Parambir S. Dulai et al.
HEPATOLOGY (2017)
Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease
S. Lefere et al.
INTERNATIONAL JOURNAL OF OBESITY (2017)
Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
Tobias Puengel et al.
PLOS ONE (2017)
Liver Fibrosis: From Pathogenesis to Novel Therapies
Ralf Weiskirchen et al.
DIGESTIVE DISEASES (2016)
Histidine-Rich Glycoprotein Promotes Macrophage Activation and Inflammation in Chronic Liver Disease
Matthias Bartneck et al.
HEPATOLOGY (2016)
Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury
Jana C. Mossanen et al.
HEPATOLOGY (2016)
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Giulio Marchesini et al.
JOURNAL OF HEPATOLOGY (2016)
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
Eric Lefebvre et al.
PLOS ONE (2016)
Roles of FGFs As Paracrine or Endocrine Signals in Liver Development, Health, and Disease
Nobuyuki Itoh et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Fibrosis Stage Is the Strongest Predictor for Disease-Specific Mortality in NAFLD After Up to 33 Years of Follow-Up
Mattias Ekstedt et al.
HEPATOLOGY (2015)
Dual effects of fibroblast growth factor 21 on hepatic energy metabolism
Ricardo J. Samms et al.
JOURNAL OF ENDOCRINOLOGY (2015)
Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding
Kathleen R. Markan et al.
DIABETES (2014)
Pharmacological Inhibition of the Chemokine C-C Motif Chemokine Ligand 2 (Monocyte Chemoattractant Protein 1) Accelerates Liver Fibrosis Regression by Suppressing Ly-6C+ Macrophage Infiltration in Mice
Christer Baeck et al.
HEPATOLOGY (2014)
Utility and Appropriateness of the Fatty Liver Inhibition of Progression (FLIP) Algorithm and Steatosis, Activity, and Fibrosis (SAF) Score in the Evaluation of Biopsies of Nonalcoholic Fatty Liver Disease
Pierre Bedossa
HEPATOLOGY (2014)
An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis
Masahiko Matsumoto et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2013)
Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research
David E. Kleiner et al.
SEMINARS IN LIVER DISEASE (2012)
Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The Multiple Parallel Hits Hypothesis
Herbert Tilg et al.
HEPATOLOGY (2010)
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Tamer Coskun et al.
ENDOCRINOLOGY (2008)
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2
John Willy Haukeland et al.
JOURNAL OF HEPATOLOGY (2006)
The natural history of nonalcoholic fatty liver disease: A population-based cohort study
LA Adams et al.
GASTROENTEROLOGY (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
FGF-21 as a novel metabolic regulator
A Kharitonenkov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
分享论文
